Jump to Navigation

Publicaties 2006

Publicaties 2006:

  • Birnie E, Bonsel GJ, de Haas M, Koelewijn JM, van der Schoot CE, Vrijkotte TGM, editors. Opsporing en Preventie Zwangerschapsimmunisatie. Evaluatie van de IEA-screening. Evaluatie van de antenatale anti-D-profylaxe. Amsterdam: Sanquin Bloedvoorziening / Afd. Sociale Geneeskunde, AMC; 2006. (203pp.) (ISBN 90-5267-030-7 978-90-5267-030-0)

 

  • Borghans JA, Bredius RG, Hazenberg MD, Roelofs H, Jol-van der Zijde EC, Heidt J, Otto SA, Kuijpers TW, Fibbe WE, Vossen JM, Miedema F, van Tol MJ. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. BLOOD 2006;108(2):763-769.     [ PubMed ]

 

  • Bouman CSC, de Pont ACJM, Meijers JCM, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E. The effects of continuous venovenous hemofiltration on coagulation activation. CRIT CARE 2006;10(5):R150.     [ PubMed ]

 

  • de Haas M, Bossers BEM, Soussan AA, Ligthart PC, Schuitemaker LDM, Page-Christiaens GCML, van der Schoot CE. Non-invasive fetal RHD genotyping and fetal sexing in maternal blood. VOX SANG 2006;91(Suppl. 3):145.

 

  • de Haas M, van der Schoot CE, Beiboer SHW, Feskens M, Cheroutre G, Maaskant-van Wijkb PA. Red blood cell and platelet genotyping: from current practice to future high-throughput donor typing. TRANSFUS MED HEMOTH 2006;33(3):260-266.  

 

  • Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. BLOOD 2006;108(10):3450-3457.

 

  • Dohmen SE, Verhagen OJHM, de Groot SM, Stott LM, Aalberse RC, Urbaniak SJ, van der Schoot CE. The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donor. CLIN EXP IMMUNOL 2006;144(2):223-232.     [ PubMed ]

 

  • Dohmen SE, Verhagen OJHM, Muit J, Ligthart PC, van der Schoot CE. The restricted use of IGHV3 superspecies genes in anti-Rh is not limited to hyperimmunized anti-D donors. TRANSFUSION 2006;46(12):2162-2168.     [ PubMed ]

 

  • Grootkerk-Tax MGHM, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. TRANSFUSION 2006;46(12):2142-2148.     [ PubMed ]

 

  • Grootkerk-Tax MGHM, van Wintershoven JD, Ligthart PC, van Rhenen DJ, van der Schoot CE, Maaskant-van Wijk PA. RHD(T201R, F223V) cluster analysis in five different ethnic groups and serologic characterization of a new Ethiopian variant DARE, the DIII type 6, and the RHD(F223V). TRANSFUSION 2006;46(4):606-615.     [ PubMed ]

 

  • Hagenbeek A. Annual haematology meeting attracts record attendance. EUR J HOSP PHARM 2006;12(4):17.  

 

  • Hagenbeek A. Rituximab-onderhoudsbehandeling bij patiënten met folliculaisr lymfoom in eerste remissie: de PRIMA/HOVON73-studie. NED TIJDSCHR HEMATOL 2006;3(2):77-79.  

 

  • Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J CLIN ONCOL 2006;24(10):1590-1596.     [ PubMed ]

 

  • Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ. Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial. AM HEART J 2006;152(3):434-441.     [ PubMed ]

 

  • Ivanov R, Hagenbeek A, Ebeling S. Towards immunogene therapy of hematological malignancies. EXP HEMATOL 2006;34(3):251-263.     [ PubMed ]

 

  • Ivanov R, Hol S, Aarts TI, Hagenbeek A, Ebeling SB. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens. CLIN EXP IMMUNOL 2006;143(1):78-84.     [ PubMed ]

 

  • Kater AP. Novel apoptosis inducting strategies in chronic lymphocytic leukemia. S.l.: s.n.; 2006. (208pp.) (PhD thesis. Supervisor(s):  van Oers MHJ, Kipps TJ; co-supervisor(s):  Eldering E) [ UvA Dissertations Online ]

 

  • Koene HR. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. PEDIATR BLOOD CANCER 2006;47(5 Suppl):703-705.     [ PubMed ]

 

  • Kramer C, Koelewijn J, de Haas M, van der Schoot CE, Vrijkotte TJ, Bonsel GJ. Opsporing en preventie van zwangerschapsimmunisatie. TIJDSCHR VERLOSKUNDIGEN 2006;Jul-aug:23-27.  

 

  • Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. AM J MED 2006;119(8):e3-e5.     [ PubMed ]

 

  • Linthorst GE. Fabry disease revisted. Clinical and laboratory studies at the advent of enzyme supplementation therapy. S.l.: s.n.; 2006. (297pp.) (PhD thesis. Supervisor(s):  Aerts JMFG, van Oers MHJ; co-supervisor(s):  Hollak CEM) [ UvA Dissertations Online ]

 

  • Mous R, Savage P, Remmerswaal EBM, van Lier RAW, Eldering E, van Oers MHJ. Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. LEUKEMIA 2006;20(6):1096-1102.     [ PubMed ]

 

  • Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol ADG, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BMP, Bosq J, Vovk M, Verschueren TAM, Pény AM, Girinsky T, Raemaekers JMM, Henry-Amar M. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J CLIN ONCOL 2006;24(19):3128-3135.     [ PubMed ]

 

  • Page-Christiaens GCML, Bossers B, van der Schoot CE, de Haas M. Use of bi-allelic insertion/deletion polymorphisms as a positive control for fetal genotyping in maternal blood: first clinical experience. ANN NY ACAD SCI 2006;1075:123-129.     [ PubMed ]

 

  • Piriou ERWAN, van Dort K, Weel JFL, Bemelman FJ, Gamadia LE, van Oers MHJ, van Baarle D. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient. CLIN IMMUNOL 2006;119(1):16-20.     [ PubMed ]

 

  • Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J VIROL 2006;80(2):802-809.     [ PubMed ]

 

  • Rubin BK, Kater AP, Goldstein AL. Thymosin beta 4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. CHEST 2006;130(5):1433-1440.  

 

  • Smit LA, van Maldegem F, Langerak AW, van der Schoot CE, de Wit MJ, Bea S, Campo E, Bende RJ, van Noesel CJM. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. HAEMATOL-HEMATOL J 2006;91(7):903-911.     [ PubMed ]

 

  • Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. NETH J MED 2006;64(10):356-363.  

 

  • Tijssen MR, van der Schoot CE, Voermans C, Zwaginga JJ. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. TRANSFUS MED REV 2006;20(4):283-293.     [ PubMed ]

 

  • van de Donk NWCJ, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MHJ, Nagler A, Verdonck LF, Lokhorst HM. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. BONE MARROW TRANSPL 2006;37(12):1135-1141.     [ PubMed ]

 

  • van de Donk NWCJ, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MHJ, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. BLOOD 2006;107(8):3415-3416.     [ PubMed ]

 

  • van den Born BJH, Koene HR, Koopmans RP, Hart W. Klinisch denken en beslissen in de praktijk. Een 39-jarige vrouw met sufheid, hypertensie en hemolyse. NED TIJDSCHR GENEESKD 2006;150(9):481-488.     [ PubMed ]

 

  • van der Schoot CE, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LGC, de Haas M. Non-invasive antenatal RHD typing. TRANSFUS CLIN BIOL 2006;13(1-2):53-57.     [ PubMed ]

 

  • van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. GENE THER 2006;13(9):789-797.     [ PubMed ]

 

  • van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. CLIN CANCER RES 2006;12(13):4027-4035.     [ PubMed ]

 

  • van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. BLOOD 2006;108(10):3295-3301.     [ PubMed ]

 

  • van Rijn RS. Preclinical evaluation of human T lymphocytes in RAG2-/-γc-/- mice. Utrecht: s.n.; 2006. (-pp.) (PhD thesis. Supervisor(s):  Hagenbeek A; co-supervisor(s):  Ebeling SB)

 

  • Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. BLOOD COAGUL FIBRIN 2006;17(6):445-451.  

 

  • Wieland CW, Kerver ME, Florquin S, Nolte MA, Borst J, van Lier R, van Oers MHJ, van der Poll T. CD27 contributes to the early systemic immune response to Mycobacterium tuberculosis infection but does not affect outcome. INT IMMUNOL 2006;18(11):1531-1539.     [ PubMed ]

 

  • Zeerleder S. The struggle to detect circulating DNA. CRIT CARE 2006;10(3):142.  

 

  • Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. THROMB RES 2006;118(2):205-212.  
Auteur: B.M.J.M. Odijk, versie: 0, 19-03-2019